Fate Therapeutics has been granted a patent for identifying compounds that enhance immune cells for adoptive cell therapies. The method involves culturing immune cells to increase specific subpopulations, improving efficacy in treating human subjects. GlobalData’s report on Fate Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Fate Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Fate Therapeutics, T-cell culturing was a key innovation area identified from patents. Fate Therapeutics's grant share as of April 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Cell therapy for treating human subjects with modulated immune cells

Source: United States Patent and Trademark Office (USPTO). Credit: Fate Therapeutics Inc

A recently granted patent (Publication Number: US11932870B2) discloses a method for treating a human subject by administering a therapeutic composition containing modulated immune cells. These immune cells are produced by culturing a population of immune cells in a culture medium with the inhibition of BCR-ABL tyrosine kinase, leading to an increase in specific subpopulations of T cells expressing CD62L and CCR7. The therapeutic composition, containing these modulated T cells, is administered in a therapeutically effective amount for adoptive cell therapy in the human subject in need.

Furthermore, the patent claims cover various aspects of the method, including the preparation of the therapeutic composition by isolating specific subpopulations of T cells, the source of the immune cells from various tissues or subjects with different health conditions, the differentiation of immune cells from different types of stem cells or progenitor cells, and the genomic engineering of immune cells to express specific receptors. The method also involves inhibiting BCR-ABL tyrosine kinase using a specific compound, resulting in the modulation of T cells with specific gene expressions and memory subpopulations. Additionally, the patent covers the use of CAR-T cells and specifies the inclusion of CD8+ or CD4+ T cells in the therapeutic composition.

To know more about GlobalData’s detailed insights on Fate Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies